Literature DB >> 15042294

["Seronegative" myasthenia with antibodies against muscle-specific tyrosine-kinase].

B Hain1, F Hanisch, M Deschauer.   

Abstract

About 10-20% of patients with generalized myasthenia gravis do not have acetylcholin receptor (AChR) antibodies and are referred to as having "seronegative" myasthenia. Recently, antibodies to muscle-specific kinase (MuSK), which mediates aggregation of AChR, were detected in half of these patients. We investigated six patients with seronegative myasthenia and identified two characteristic cases with MuSK antibodies. A 56-year-old woman developed ptosis and double vision followed by bulbar symptoms and respiratory insufficiency. She showed moderate response to treatment with pyridostigmine and no response to prednisolone, azathioprine, or intravenous immunoglobulin but good response to several plasma exchanges. A 46-year-old man with exercise-induced weakness of the upper limbs and mild bulbar and respiratory symptoms had a milder course for 9 years. These cases highlight the clinical spectrum of MuSK-positive myasthenia and the differences to AChR-positive myasthenia with predominant bulbar symptoms and often severe symptoms with respiratory insufficiency. Finally, they illustrate the therapeutic difficulties with less response to pyridostigmine and immunosuppressive drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042294     DOI: 10.1007/s00115-003-1672-5

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  26 in total

1.  AChR phosphorylation and indirect inhibition of AChR function in seronegative MG.

Authors:  C P Plested; T Tang; I Spreadbury; E T Littleton; U Kishore; A Vincent
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

2.  Seronegative myasthenia gravis: clinical features, response to therapy and synthesis of acetylcholine receptor antibodies in vitro.

Authors:  B Birmanns; T Brenner; O Abramsky; I Steiner
Journal:  J Neurol Sci       Date:  1991-04       Impact factor: 3.181

3.  The thymus in seronegative myasthenia gravis patients.

Authors:  N Willcox; M Schluep; M A Ritter; J Newsom-Davis
Journal:  J Neurol       Date:  1991-08       Impact factor: 4.849

4.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

5.  Anti-AChR-negative myasthenia gravis: clinical and immunological features.

Authors:  A Evoli; E Bartoccioni; A P Batocchi; F Scuderi; P Tonali
Journal:  Clin Invest Med       Date:  1989-04       Impact factor: 0.825

6.  Modulation of acetylcholine receptor expression in seronegative myasthenia gravis.

Authors:  S Poea; T Guyon; J Bidault; C Bruand; V Mouly; S Berrih-Aknin
Journal:  Ann Neurol       Date:  2000-11       Impact factor: 10.422

Review 7.  Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets.

Authors:  Angela Vincent; John Bowen; John Newsom-Davis; John McConville
Journal:  Lancet Neurol       Date:  2003-02       Impact factor: 44.182

8.  Clinical heterogeneity of seronegative myasthenia gravis.

Authors:  A Evoli; A P Batocchi; M Lo Monaco; S Servidei; L Padua; L Majolini; P Tonali
Journal:  Neuromuscul Disord       Date:  1996-05       Impact factor: 4.296

9.  Seronegative generalized myasthenia gravis: low frequency of thymic pathology.

Authors:  P K Verma; J J Oger
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

10.  Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement.

Authors:  Flavia Scuderi; Mariapaola Marino; Lucrezia Colonna; Francesca Mannella; Amelia Evoli; Carlo Provenzano; Emanuela Bartoccioni
Journal:  Lab Invest       Date:  2002-09       Impact factor: 5.662

View more
  1 in total

1.  Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies.

Authors:  Giovanna Cenacchi; Valentina Papa; Papa Valentina; Marina Fanin; Fanin Marina; Elena Pegoraro; Pegoraro Elena; Corrado Angelini; Angelini Corrado
Journal:  J Neurol       Date:  2010-11-19       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.